Septerna, Inc. (SEPN)
- Previous Close
6.73 - Open
10.82 - Bid 9.86 x 100
- Ask 10.24 x 200
- Day's Range
8.51 - 11.36 - 52 Week Range
4.17 - 28.99 - Volume
37,471,847 - Avg. Volume
511,418 - Market Cap (intraday)
452.28M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-7.26 - Earnings Date Mar 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.33
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. The company also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
septerna.comRecent News: SEPN
View More
Related Videos: SEPN
Performance Overview: SEPN
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SEPN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SEPN
View MoreValuation Measures
Market Cap
299.59M
Enterprise Value
-25.86M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
61.92
Price/Book (mrq)
0.71
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.20%
Return on Equity (ttm)
-27.05%
Revenue (ttm)
1.07M
Net Income Avi to Common (ttm)
-71.8M
Diluted EPS (ttm)
-7.26
Balance Sheet and Cash Flow
Total Cash (mrq)
350.92M
Total Debt/Equity (mrq)
6.07%
Levered Free Cash Flow (ttm)
-25.69M
Research Analysis: SEPN
View MoreResearch Reports: SEPN
View MoreDaily – Vickers Top Insider Picks for 05/14/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 05/13/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 05/12/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 05/09/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.